MA35932B1 - Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine - Google Patents
Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitineInfo
- Publication number
- MA35932B1 MA35932B1 MA37338A MA37338A MA35932B1 MA 35932 B1 MA35932 B1 MA 35932B1 MA 37338 A MA37338 A MA 37338A MA 37338 A MA37338 A MA 37338A MA 35932 B1 MA35932 B1 MA 35932B1
- Authority
- MA
- Morocco
- Prior art keywords
- activating enzyme
- chemical entities
- ubiquitin activating
- pyrazolopyrimidinyl
- inhibitors
- Prior art date
Links
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 title abstract 2
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 title abstract 2
- -1 Pyrazolopyrimidinyl Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des entités chimiques inhibiteurs de l'enzyme d'activation de l'ubiquitine (uae), dont chacune est un composé de formule (i), ou un sel pharmaceutiquement acceptable de celles-ci, dans laquelle y est formule (2) et w, z, xy, ry1, ry2 et ry3 sont tels que définis dans la description; des compositions pharmaceutiques comportant les entités chimiques; et des procédés d'utilisation des entités chimiques. Ces entités chimiques sont utiles pour le traitement de troubles, en particulier des troubles de prolifération cellulaire, y compris des cancers.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600070P | 2012-02-17 | 2012-02-17 | |
| PCT/US2013/026113 WO2013123169A1 (fr) | 2012-02-17 | 2013-02-14 | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35932B1 true MA35932B1 (fr) | 2014-12-01 |
Family
ID=48982730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37338A MA35932B1 (fr) | 2012-02-17 | 2014-09-10 | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9290500B2 (fr) |
| EP (3) | EP3173413B1 (fr) |
| JP (1) | JP6122877B2 (fr) |
| KR (1) | KR20140123104A (fr) |
| CN (1) | CN104136399B (fr) |
| AR (1) | AR092797A1 (fr) |
| BR (1) | BR112014020365B1 (fr) |
| CA (1) | CA2864672C (fr) |
| CL (1) | CL2014002181A1 (fr) |
| CO (1) | CO7071135A2 (fr) |
| CR (1) | CR20140380A (fr) |
| DO (1) | DOP2014000187A (fr) |
| EA (1) | EA035020B1 (fr) |
| EC (1) | ECSP14019113A (fr) |
| ES (1) | ES2739150T3 (fr) |
| GE (1) | GEP201706687B (fr) |
| HK (1) | HK1201817A1 (fr) |
| IL (1) | IL234016A0 (fr) |
| MA (1) | MA35932B1 (fr) |
| MX (1) | MX352963B (fr) |
| NZ (1) | NZ628969A (fr) |
| PE (1) | PE20142244A1 (fr) |
| PH (1) | PH12014501832A1 (fr) |
| SG (2) | SG10201606581RA (fr) |
| TN (1) | TN2014000351A1 (fr) |
| TW (1) | TWI593688B (fr) |
| UA (1) | UA116534C2 (fr) |
| UY (1) | UY34629A (fr) |
| WO (1) | WO2013123169A1 (fr) |
| ZA (1) | ZA201406103B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| EP3173413B1 (fr) | 2012-02-17 | 2019-05-01 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine |
| WO2014022744A1 (fr) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de pyrrolopyrimidinyle substitué par indole d'uba6 |
| BR112015032902A8 (pt) | 2013-07-02 | 2019-12-24 | Millennium Pharm Inc | compostos de heteroarila, seus usos e composições farmacêuticas |
| EP3901159A1 (fr) * | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Composés hétéroaryles utiles en tant qu'inhibiteurs de l'enzyme d'activation de la protéine sumo |
| TW201628621A (zh) * | 2014-10-29 | 2016-08-16 | 千禧製藥公司 | 泛素活化酶抑制劑及輻射之施用 |
| EP3212650B1 (fr) | 2014-10-29 | 2021-02-17 | Millennium Pharmaceuticals, Inc. | Administration d'inhibiteur d'enzyme activant l'ubiquitine et agents chimiothérapeutiques |
| MY210039A (en) | 2018-10-30 | 2025-08-22 | Kronos Bio Inc | Compounds, compositions, and methods for modulating cdk9 activity |
| CN117412973A (zh) * | 2021-05-31 | 2024-01-16 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
| WO2023021498A1 (fr) * | 2021-08-16 | 2023-02-23 | Moya Bio Ltd. | Analogues de nucléosides à base d'azole et de furane fusionnés et leurs utilisations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023901A1 (en) | 2002-02-28 | 2004-02-05 | Cook Phillip D. | Nucleoside 5'-monophosphate mimics and their prodrugs |
| WO2004022559A1 (fr) | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines utilisees en tant qu'inhibiteurs des kinases cycline-dependantes |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1701073B (zh) | 2002-09-04 | 2011-06-22 | 先灵公司 | 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶 |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| EP1608652A1 (fr) | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Composes pyrazolopyrimidines et leur utilisation en medecine |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| JP2008503591A (ja) | 2004-06-22 | 2008-02-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ユビキチンリガーゼ阻害剤 |
| AU2006210422B2 (en) | 2005-02-04 | 2012-09-13 | Takeda Pharmaceutical Company Limited | Inhibitors of E1 activating enzymes |
| WO2007044426A2 (fr) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines utilisees comme inhibiteurs de proteines kinases |
| CN106008512B (zh) | 2006-02-02 | 2019-03-12 | 千禧药品公司 | E1活化酶抑制剂 |
| JP4953472B2 (ja) * | 2006-02-28 | 2012-06-13 | ラム・リサーチ・アクチエンゲゼルシヤフト | ディスク状物品を液体処理する装置及び方法 |
| HRP20110017T1 (hr) * | 2006-08-08 | 2011-02-28 | Millennium Pharmaceuticals | Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| JP5539864B2 (ja) | 2007-06-12 | 2014-07-02 | アカオゲン，インコーポレーテッド | 抗菌剤 |
| KR101925902B1 (ko) * | 2007-08-02 | 2018-12-06 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ1 활성화 효소 억제제의 합성 방법 |
| WO2009082691A1 (fr) | 2007-12-21 | 2009-07-02 | Board Of Regents, University Of Texas System | Inhibiteurs de dihydroorotate déshydrogénase présentant une activité antipaludéenne sélective |
| WO2010086040A1 (fr) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines pour traitement de la myopathie de duchenne |
| WO2010088518A2 (fr) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Modulateurs hétérocycliques du gpr119 pour le traitement de maladies |
| SG10201402148SA (en) * | 2009-05-14 | 2014-07-30 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| EP3064204A1 (fr) | 2010-03-01 | 2016-09-07 | GTx, Inc. | Composes pour le traitement du cancer |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| MX2014002015A (es) | 2011-08-24 | 2014-03-27 | Millennium Pharm Inc | Inhibidores de la enzima activadora de nedd8. |
| EP3173413B1 (fr) | 2012-02-17 | 2019-05-01 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine |
| WO2014022744A1 (fr) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de pyrrolopyrimidinyle substitué par indole d'uba6 |
| BR112015032902A8 (pt) | 2013-07-02 | 2019-12-24 | Millennium Pharm Inc | compostos de heteroarila, seus usos e composições farmacêuticas |
| EP3901159A1 (fr) | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Composés hétéroaryles utiles en tant qu'inhibiteurs de l'enzyme d'activation de la protéine sumo |
-
2013
- 2013-02-14 EP EP16205139.5A patent/EP3173413B1/fr active Active
- 2013-02-14 GE GEAP201313560A patent/GEP201706687B/en unknown
- 2013-02-14 WO PCT/US2013/026113 patent/WO2013123169A1/fr not_active Ceased
- 2013-02-14 SG SG10201606581RA patent/SG10201606581RA/en unknown
- 2013-02-14 NZ NZ628969A patent/NZ628969A/en not_active IP Right Cessation
- 2013-02-14 BR BR112014020365-2A patent/BR112014020365B1/pt not_active IP Right Cessation
- 2013-02-14 CA CA2864672A patent/CA2864672C/fr active Active
- 2013-02-14 US US13/767,314 patent/US9290500B2/en active Active
- 2013-02-14 CN CN201380009784.8A patent/CN104136399B/zh active Active
- 2013-02-14 SG SG11201404757WA patent/SG11201404757WA/en unknown
- 2013-02-14 JP JP2014557765A patent/JP6122877B2/ja not_active Expired - Fee Related
- 2013-02-14 MX MX2014009944A patent/MX352963B/es active IP Right Grant
- 2013-02-14 HK HK15102227.4A patent/HK1201817A1/xx unknown
- 2013-02-14 ES ES16205139T patent/ES2739150T3/es active Active
- 2013-02-14 EA EA201400831A patent/EA035020B1/ru not_active IP Right Cessation
- 2013-02-14 UA UAA201409297A patent/UA116534C2/uk unknown
- 2013-02-14 EP EP19170607.6A patent/EP3536692B1/fr active Active
- 2013-02-14 PE PE2014001278A patent/PE20142244A1/es active IP Right Grant
- 2013-02-14 EP EP13748707.0A patent/EP2814791A4/fr not_active Withdrawn
- 2013-02-14 KR KR1020147025556A patent/KR20140123104A/ko not_active Ceased
- 2013-02-15 AR ARP130100480A patent/AR092797A1/es unknown
- 2013-02-15 UY UY0001034629A patent/UY34629A/es not_active Application Discontinuation
- 2013-02-18 TW TW102105676A patent/TWI593688B/zh not_active IP Right Cessation
-
2014
- 2014-08-07 IL IL234016A patent/IL234016A0/en unknown
- 2014-08-11 TN TNP2014000351A patent/TN2014000351A1/fr unknown
- 2014-08-12 CR CR20140380A patent/CR20140380A/es unknown
- 2014-08-13 PH PH12014501832A patent/PH12014501832A1/en unknown
- 2014-08-14 CL CL2014002181A patent/CL2014002181A1/es unknown
- 2014-08-15 DO DO2014000187A patent/DOP2014000187A/es unknown
- 2014-08-20 ZA ZA2014/06103A patent/ZA201406103B/en unknown
- 2014-09-10 MA MA37338A patent/MA35932B1/fr unknown
- 2014-09-16 CO CO14205517A patent/CO7071135A2/es unknown
- 2014-09-17 EC ECIEPI201419113A patent/ECSP14019113A/es unknown
-
2016
- 2016-02-19 US US15/048,007 patent/US9663525B2/en active Active
-
2017
- 2017-04-17 US US15/488,800 patent/US9796725B2/en active Active
- 2017-09-08 US US15/699,818 patent/US10202389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35932B1 (fr) | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MX2014000536A (es) | Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa. | |
| MA45920B1 (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| MA33032B1 (fr) | Pyrimidines condensees | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
| MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
| UA107100C2 (xx) | Конденсовані гетероароматичні піролідинони як інгібітори syk | |
| EP4275756A3 (fr) | Dérivés de bipyrazole servant d'inhibiteurs de jak | |
| EP3363797A8 (fr) | Forme de dosage orale d'inhibiteurs de kinase régulant le signal d'apoptose | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| NZ590650A (en) | Buprenorphine analogs | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TN2012000534A1 (en) | Pyrazole compounds as sigma receptor inhibitors | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA39186A1 (fr) | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose | |
| MA32997B1 (fr) | Macrolide anti-inflammatoire | |
| MY152685A (en) | Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
| MA45867B1 (fr) | Modulateurs du récepteur des oestrogènes | |
| MA38206B1 (fr) | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
| MA38207A2 (fr) | Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées |